Framing the benefits of cancer clinical trials

Archives of Pediatrics and Adolescent Medicine

Volumn 164, Issue 3, 2010, Pages 293-294

  Joffe, Steven ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; DEMOGRAPHY; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RESEARCH SUBJECT; ATTITUDE TO HEALTH; CHILD; CLINICAL TRIAL; NEOPLASM; NOTE; OUTCOME ASSESSMENT; TREATMENT OUTCOME;

CHILD; CLINICAL TRIALS AS TOPIC; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 77950362254     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2009.293     Document Type: Editorial

References (15)

1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720-2726.
2. Rettig RA, Jacobson PA, Farquhar CM, Aubry WM. False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford, England: Oxford University Press; 2007.
3. Miller FG, Rosenstein DL, DeRenzo EG. Professional integrity in clinical research. JAMA. 1998;280(16):1449-1454.
4. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/f- guidelines .asp. Accessed November 24, 2009.
5. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004;363(9405):263-270.
6. Gross CP, Krumholz HM, Van Wye G, Emanuel EJ, Wendler D. Does random treatment assignment cause harm to research participants? PLoS Med. 2006;3 (6):e188.
7. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? evidence for a "trial effect". J Clin Epidemiol. 2001; 54(3):217-224.
8. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev. 2008;(3):MR000009.
9. Robinson WR, Ritter J, Rogers AS, Tedjarati S, Lieberenz C. Clinical trial participation is associated with improved outcome in women with ovarian cancer. Int J Gynecol Cancer. 2009;19(1):124-128.
10. Stevens JM, Macdougall F, Jenner M, Oakervee H, Cavenagh J, Lister AT. Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centre. Br J Haematol. 2009;145 (1):40-44.
11. Koschmann C, Thomson B, Hawkins DS. No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia. Arch Pediatr Adolesc Med. 2010;164(3):214-217.
12. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987;17(2):20-24.
13. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367(9519):1319-1327.
14. Karjalainen S, Palva I. Do treatment protocols improve end results? a study of survival of patients with multiple myeloma in Finland. BMJ. 1989;299(6707): 1069-1072.
15. 5-year relative survival rates by year dx, by age at diagnosis/death, acute lymphocytic leukemia, all races, both sexes, 1975-2001. Surveillance Epidemiology and End Results Web site. http://seer.cancer.gov/faststats/ selections.php?run&output =1&data=4&statistic=6&cancer= 90&year=200905&race=1&sex=1&subSite=92 &series=age&age= 15. Accessed November 25, 2009.